{
  "id": 20988420,
  "title": "'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers",
  "url": "https://urgent.news/2026/11/21/pan-ras-molecular-glue-is-a-safe-and-effective-treatment-for-lung-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-21T02:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html"
  },
  "original_language": "en",
  "account": "The AURORAS-1 Phase I clinical trial evaluated the safety and efficacy of a drug called ERAS-0015 in treating lung and pancreatic cancers driven by mutations in the RAS gene. Conducted at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the study involved 148 patients and demonstrated that ERAS-0015 is safe and can cause tumors to shrink in these hard-to-treat diseases. Dr. Judy Wang, a medical oncologist, reported that ERAS-0015, a pan-RAS molecular glue, brought proteins together at the molecular level to block tumor growth signals from multiple cancer-driving RAS mutations. The trial showed a 44% response rate in pancreatic cancer patients and a 60% response rate in lung cancer patients treated with ERAS-0015. The drug was also well-tolerated, with few severe side effects. Further study in larger numbers of patients is necessary to confirm the safety and efficacy of ERAS-0015.",
  "summary": "Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}